Astellas Pharma (United States)

Recent papers from Astellas Pharma (United States)

1. A seamless dose-optimization design for monotherapy and combination therapyStatistical Methods in Medical Research · 2026
2. Early Clinical Adoption and Treatment Patterns of Avacincaptad Pegol for Geographic Atrophy in the USA: An IRIS® Registry AnalysisOphthalmology and Therapy · 2026
3. Bothersome VMS associated with menopause: a survey of the impact on women and their partners in the United StatesMenopause The Journal of The North American Menopause Society · 2026
4. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trialThe Lancet · 2015
5. BOIN12 ‐ PFS : A Bayesian Optimal Interval Phase I / II Design Incorporating Progression‐Free Survival EndpointPharmaceutical Statistics · 2026
6. From Real World Data to Real Impact: A Co‐Medication Framework for Lung Cancer to Advance DDI Assessment and Patient‐Centric Drug DevelopmentClinical and Translational Science · 2026
7. Real‐World Overall Survival With Abiraterone Acetate and Enzalutamide in Patients With Chemotherapy‐Naïve Metastatic Castration‐Resistant Prostate Cancer From the Flatiron Electronic Health Records DatabaseCancer Medicine · 2026
8. Cardiovascular Risk Triage Schema for Patients With Prostate Cancer Treated With Hormone TherapyJCO Oncology Practice · 2026
9. Zolbetuximab plus chemotherapy versus immune checkpoint inhibitor regimens by programmed death-ligand 1 combined positive score in locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma: a Bayesian network meta-analysisESMO Open · 2026
10. Exposure–Response Analysis of Enfortumab Vedotin Plus Pembrolizumab as First‐Line Therapy for Locally Advanced or Metastatic Urothelial CancerClinical Pharmacology & Therapeutics · 2026
11. Gilteritinib plus azacitidine in patients with newly diagnosed FLT3 mutation-positive acute myeloid leukemia who were ineligible for intensive chemotherapy: final results of the phase III LACEWING studyHaematologica · 2026
12. Enfortumab vedotin induces immunogenic cell death and shows enhanced preclinical antitumor activity when combined with a PD-1 inhibitorCell Reports Medicine · 2026
13. How low do you need to go? Association between various prostate‐specific antigen response measures and clinical outcomes in metastatic castration‐sensitive prostate cancer in the Veterans Health Administration dataCancer · 2026
14. Evaluating AI Performance in Systematic Literature Reviews for HEOR: A Case StudyJournal of health economics and outcomes research · 2026
15. Impact of vasomotor symptoms on women in the workplace: Results from a non-interventional survey in the United StatesMaturitas · 2026
16. Imaging Characteristics of Pylorogastric, Duodenogastric, and True‐Gastrogastric Intussusception in 25 Dogs and One CatVeterinary Radiology & Ultrasound · 2026
17. Regional practice differences significantly impact benefit from post-HCT gilteritinib for FLT3-ITD AMLBlood Advances · 2026
18. A Randomized Basket Trial Design for Dose Optimization Based on Bayesian Model Averaging Using Spike‐and‐Slab PriorsStatistics in Medicine · 2026
19. Matching-adjusted indirect comparison of enzalutamide versus apalutamide with androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancerFuture Oncology · 2026
20. Clinicians’ Perspectives on the Impact of Different Attributes of Androgen Receptor Pathway Inhibitors on Prostate Cancer Treatment Preferences and Compliance in MexicoOncology and Therapy · 2026